Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: Haloperidol vs. quetiapine

International Journal of Neuropsychopharmacology

Volumn 9, Issue 5, 2006, Pages 507-516

  Savaskan, Egemen ^a   Schnitzler, Corina ^a   Schröder, Carmen ^a   Cajochen, Christian ^a   Müller Spahn, Franz ^a   Wirz Justice, Anna ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Actimetry; Alzheimer's disease; Behavioural symptoms; Haloperidol; Quetiapine

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; HALOPERIDOL; QUETIAPINE;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ANXIETY; ARTERY DISEASE; ARTERY TONE; ARTICLE; BEHAVIOR DISORDER; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DELUSION; DEPRESSION; DISEASE EXACERBATION; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROENTERITIS; HUMAN; INSTRUMENTAL ACTIVITIES OF DAILY LIVING; LOCOMOTION; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NIGHT SLEEP; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; RESTLESSNESS; SLEEP WAKING CYCLE; SYNCOPE; TREATMENT DURATION; TREATMENT OUTCOME; VERBAL MEMORY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BEHAVIOR; CHRONOBIOLOGY DISORDERS; COGNITION; DIBENZOTHIAZEPINES; FEMALE; GERIATRIC ASSESSMENT; HALOPERIDOL; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 33750221838     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006036     Document Type: Article

References (37)

1. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, Ruther E (2004). Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology 174, 421-429.
2. Cummings JL, Mega M, Gray K, Rosenberg-Thomson S, Carusi DA, Gornbein J (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
3. Davis P, Baskys A (2002). Quetiapine effectively reduces psychotic symptoms in patients with Lewy body dementia: an advantage of the unique pharmacological profile? Brain Aging 2, 49-53.
4. DeVane CL, Nemeroff CB (2001). Clinical pharmacokinetics of quetiapine: an atypical neuroleptic. Clinical Pharmacokinetics 40, 509-522.
5. Dewey Jr. RB, O'Suilleabhain PE (2000). Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 55, 1753-1754.
6. Fahy S, Fahy TJ (2000). Induction of manic symptoms by novel antipsychotics. British Journal of Psychiatry 176, 597.
7. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M (1999). Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Movement Disorders 14, 484-487.
8. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH (2002). Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. Journal of Clinical Psychiatry 63, 513-515.
9. Fernandez HH, Wu C-K, Ott BR (2003). Pharmacotherapy of dementia with Lewy bodies. Expert Opinion on Pharmacotherapy 4, 2027-2037.
10. Fontana-Gasio P, Kräuchi K, Cajochen C, Van Sommeren E, Amrhein I, Pache M, Savaskan E, Wirz-Justice A (2003). Dawn-dusk simulation light therapy of disturbed circadian rest-activity cycles in demented elderly. Experimental Gerontology 38, 207-216.
11. Fujikawa T, Takahashi T, Kinoshita A, Kajiyama H, Kurata A, Yamashita H, Yamawaki S (2004). Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Pharmacopsychiatry 49, 201-204.
12. Ghaemi SN, Katzow JJ (1999). The use of quetiapine for treatment-resistant bipolar disorder: a case series. Annals of Clinical Psychiatry 11, 137-140.
13. Heyman A, Fillenbaum GG, Mirra SS (1990). Consortium to Establish a Registry for Alzheimer's Disease (CERAD): clinical, neuropsychological, and neuropathological components. Aging 2, 415-424.
14. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA (2004). Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. British Medical Journal 329, 75-80.
15. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC (2000). Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. American Journal of Psychiatry 157, 708-714.
16. McManus DQ, Arvanitis LA, Kowalcyk BB (1999). Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. Journal of Clinical Psychiatry 60, 292-298.
17. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A (1988). Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychologocal assessment of Alzheimer's disease. Psychopharmacology Bulletin 24, 641-652.
18. Motsinger CD, Perron GA, Lacy TJ (2003). Use of atypical antipsychotic drugs in patients with dementia. American Family Physician 67, 2335-2340.
19. Pollak CP, Stokes PE (1997). Circadian rest-activity rhythms in demented and nondemented older community residents and their caregivers. Journal of the American Geriatrics Society 45, 446-452.
20. Profenno LA, Tariot PN (2004). Pharmacologic management of gitation in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 17, 65-77.
21. Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sciences 68, 29-39.
22. Sajatovic M, Brescan DW, Perez DE, DiGiovanni SK, Hattb H, Ray JB, Bingham CR (2001). Quetiapine alone and added to a mood stabilizer for serious mood disorders. Journal of Clinical Psychiatry 62, 728-732.
23. Sajatovic M, Mullen JA, Sweitzer DE (2002). Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. Journal of Clinical Psychiatry 63, 1156-1163.
24. Saller CF, Salama AI (1993). Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112, 285-292.
25. Salzman C (2001). Treatment of the agitation of late-life psychosis and Alzheimer's disease. European Psychiatry 16 (Suppl. 1), 25-28.
26. Scharre DW, Chang S-I (2002). Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Disease and Associated Disorders 16, 128-130.
27. Spiegel R, Brunner C, Ermini-Fünfschilling D, Monsch A, Notter M, Puxty J, Tremmel L (1991). A new behavioural assessment for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients). Journal of the American Geriatric Society 39, 339-347.
28. Sultzer DL (2004). Psychosis and antipsychotic medications in Alzheimer's disease: clinical management and research perspectives. Dementia and Geriatric Cognitive Disorders 17, 78-90.
29. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T (2003). Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy boides: a case series. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27, 549-553.
30. Tariot PN, Ismail MS (2002). Use of quetiapine in elderly patients. Journal of Clinical Psychiatry 63, 21-26.
31. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW (2000). Long-term use of quetiapine in elderly patients with psychotic disorders. Clinical Therapeutics 22, 1068-1084.
32. Tyson PJ, Roberts KH, Mortimer AM (2004). Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? International Journal of Neuroscience 114, 593-611.
33. Van Someren EJW, Hagebeuk EE, Lijzenga C, Scheltens P, de Rooij SE, Jonker C, Pot AM, Mirmiran M, Swaab DF (1996). Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biological Psychiatry 40, 259-270.
34. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL (2002). Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophrenia Research 53, 239-248.
35. Vitiello MV, Borson S (2001). Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment. CNS Drugs 15, 777-796.
36. Werth E, Savaskan E, Knoblauch V, Fontana-Gasio P, Van Sommeren EJW, Hock C, Wirz-Justice A (2002). Decline in long-term circadian rest-activity cycle organization in a patient with dementia. Journal of Geriatric Psychiatry and Neurology 15, 55-59.
37. Wirz-Justice A, Werth E, Savaskan E, Knoblauch V, Fontana-Gasio P, Müller-Spahn F (2000). Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Disease and Associated Disorders 14, 212-215.